Prolonged Treatment with DNMT Inhibitors Induces Distinct Effects in Promoters and Gene-Bodies

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Wong, Yan Fung ^a   Jakt, Lars Martin ^a   Nishikawa, Shin Ichi ^a  

^a RIKEN Center for Biosystems Dynamics Research   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DNA METHYLTRANSFERASE INHIBITOR;

ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA DEMETHYLATION; DNA METHYLATION; GENE ACTIVATION; GENE EXPRESSION; GENOME ANALYSIS; LEUKEMIA CELL; PROMOTER REGION;

AZACITIDINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; ENZYME INHIBITORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INTRANUCLEAR INCLUSION BODIES; MICROARRAY ANALYSIS; PROMOTER REGIONS, GENETIC; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 84881129991     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071099     Document Type: Article

References (50)

1. Heyn H, Esteller M, (2012) DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet 13: 679-692. doi:10.1038/nrg3270. PubMed: 22945394.
2. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, et al. (2001) Initial sequencing and analysis of the human genome. Nature 409: 860-921. doi:10.1038/35057062. PubMed: 11237011.
3. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, et al. (2001) The sequence of the human genome. Science 291: 1304-1351. doi:10.1126/science.1058040. PubMed: 11181995.
4. Saxonov S, Berg P, Brutlag DL, (2006) A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc Natl Acad Sci U S A 103: 1412-1417. doi:10.1073/pnas.0510310103. PubMed: 16432200.
5. Esteller M, (2007) Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 16: R50-9 Spec No 1: R50-59. PubMed: 17613547.
6. McDevitt MA, (2012) Clinical applications of epigenetic markers and epigenetic profiling in myeloid malignancies. Semin Oncol 39: 109-122. doi:10.1053/j.seminoncol.2011.11.003. PubMed: 22289497.
7. Baylin SB, Herman JG, (2000) DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 16: 168-174. doi:10.1016/S0168-9525(99)01971-X. PubMed: 10729832.
8. Foran JM, Shammo JM, (2012) Clinical presentation, diagnosis, and prognosis of myelodysplastic syndromes. Am J Med 125: S6-13. doi:10.1016/j.amjmed.2012.04.015. PubMed: 22735753.
9. Bejar R, Levine R, Ebert BL, (2011) Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol 29: 504-515. doi:10.1200/JCO.2010.31.1175. PubMed: 21220588.
10. Sanada M, Suzuki T, Shih LY, Otsu M, Kato M, et al. (2009) Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 460: 904-908. doi:10.1038/nature08240. PubMed: 19620960.
11. Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, et al. (2009) Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 113: 1315-1325. doi:10.1182/blood-2008-06-163246. PubMed: 18832655.
12. Figueroa ME, Skrabanek L, Li Y, Jiemjit A, Fandy TE, et al. (2009) MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 114: 3448-3458. doi:10.1182/blood-2009-01-200519. PubMed: 19652201.
13. Egger G, Liang G, Aparicio A, Jones PA, (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429: 457-463. doi:10.1038/nature02625. PubMed: 15164071.
14. Itzykson R, Fenaux P, (2011) [Hypomethylating agents for the treatment of myelodysplastic syndromes]. Bull Cancer 98: 927-934. PubMed: 21821482.
15. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, et al. (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20: 2429-2440. doi:10.1200/JCO.2002.04.117. PubMed: 12011120.
16. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, et al. (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106: 1794-1803. doi:10.1002/cncr.21792. PubMed: 16532500.
17. Irizarry RA, Ladd-Acosta C, Carvalho B, Wu H, Brandenburg SA, et al. (2008) Comprehensive high-throughput arrays for relative methylation (CHARM). Genome Res 18: 780-790. doi:10.1101/gr.7301508. PubMed: 18316654.
18. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80. doi:10.1186/gb-2004-5-10-r80. PubMed: 15461798.
19. Li LC, Dahiya R, (2002) MethPrimer: designing primers for methylation PCRs. Bioinformatics 18: 1427-1431. doi:10.1093/bioinformatics/18.11.1427. PubMed: 12424112.
20. Kumaki Y, Oda M, Okano M, (2008) QUMA: quantification tool for methylation analysis. Nucleic Acids Res 36: W170-W175. doi:10.1093/nar/gkn294. PubMed: 18487274.
21. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034. PubMed: 12184808.
22. Gautier L, Cope L, Bolstad BM, Irizarry RA, (2004) affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20: 307-315. doi:10.1093/bioinformatics/btg405. PubMed: 14960456.
23. Venables WN, Ripley BD, (2002) Modern applied statistics with S. New York: Springer Verlag. xi.: 495pp.
24. Nakagawa T, Matozaki S, Murayama T, Nishimura R, Tsutsumi M, et al. (1993) Establishment of a leukaemic cell line from a patient with acquisition of chromosomal abnormalities during disease progression in myelodysplastic syndrome. Br J Haematol 85: 469-476. PubMed: 8136267.
25. Stresemann C, Bokelmann I, Mahlknecht U, Lyko F, (2008) Azacytidine causes complex DNA methylation responses in myeloid leukemia. Mol Cancer Ther 7: 2998-3005. doi:10.1158/1535-7163.MCT-08-0411. PubMed: 18790780.
26. Mossman D, Kim KT, Scott RJ, (2010) Demethylation by 5-aza-2'-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists. BMC Cancer 10: 366. doi:10.1186/1471-2407-10-366. PubMed: 20618997.
27. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, et al. (1999) CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 96: 8681-8686. doi:10.1073/pnas.96.15.8681. PubMed: 10411935.
28. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, et al. (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38: 787-793. doi:10.1038/ng1834. PubMed: 16804544.
29. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Köhler G, et al. (2002) Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood 100: 2957-2964. doi:10.1182/blood.V100.8.2957. PubMed: 12351408.
30. Tran HT, Kim HN, Lee IK, Kim YK, Ahn JS, et al. (2011) DNA methylation changes following 5-azacitidine treatment in patients with myelodysplastic syndrome. J Korean Med Sci 26: 207-213. doi:10.3904/kjim.2011.26.2.207. PubMed: 21286011.
31. Hollenbach PW, Nguyen AN, Brady H, Williams M, Ning Y, et al. (2010) A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLOS ONE 5: e9001. doi:10.1371/journal.pone.0009001. PubMed: 20126405.
32. Negrotto S, Ng KP, Jankowska AM, Bodo J, Gopalan B, et al. (2012) CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors. Leukemia 26: 244-254. doi:10.1038/leu.2011.207. PubMed: 21836612.
33. Tsai HC, Li H, Van Neste L, Cai Y, Robert C, et al. (2012) Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21: 430-446. doi:10.1016/j.ccr.2011.12.029. PubMed: 22439938.
34. Ghoshal K, Datta J, Majumder S, Bai S, Kutay H, et al. (2005) 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol 25: 4727-4741. doi:10.1128/MCB.25.11.4727-4741.2005. PubMed: 15899874.
35. Patel K, Dickson J, Din S, Macleod K, Jodrell D, et al. (2010) Targeting of 5-aza-2'-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme. Nucleic Acids Res 38: 4313-4324. doi:10.1093/nar/gkq187. PubMed: 20348135.
36. Jin B, Ernst J, Tiedemann RL, Xu H, Sureshchandra S, et al. (2012) Linking DNA methyltransferases to epigenetic marks and nucleosome structure genome-wide in human tumor cells. Cell Rep 2: 1411-1424. doi:10.1016/j.celrep.2012.10.017. PubMed: 23177624.
37. Bashtrykov P, Jankevicius G, Smarandache A, Jurkowska RZ, Ragozin S, et al. (2012) Specificity of DNMT1 for methylation of hemimethylated CpG sites resides in its catalytic domain. Chem Biol 19: 572-578. doi:10.1016/j.chembiol.2012.03.010. PubMed: 22633409.
38. Williams K, Christensen J, Helin K, (2012) DNA methylation: TET proteins-guardians of CpG islands? EMBO Rep 13: 28-35. PubMed: 22157888.
39. Kinney SR, Pradhan S, (2013) Ten eleven translocation enzymes and 5-hydroxymethylation in mammalian development and cancer. Adv Exp Med Biol 754: 57-79. doi:10.1007/978-1-4419-9967-2_3. PubMed: 22956496.
40. Wu H, D'Alessio AC, Ito S, Wang Z, Cui K, et al. (2011) Genome-wide analysis of 5-hydroxymethylcytosine distribution reveals its dual function in transcriptional regulation in mouse embryonic stem cells. Genes Dev 25: 679-684. doi:10.1101/gad.2036011. PubMed: 21460036.
41. Williams K, Christensen J, Pedersen MT, Johansen JV, Cloos PA, et al. (2011) TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 473: 343-348. doi:10.1038/nature10066. PubMed: 21490601.
42. Gingras MC, Lapillonne H, Margolin JF, (2002) TREM-1, MDL-1, and DAP12 expression is associated with a mature stage of myeloid development. Mol Immunol 38: 817-824. doi:10.1016/S0161-5890(02)00004-4. PubMed: 11922939.
43. Klesney-Tait J, Turnbull IR, Colonna M, (2006) The TREM receptor family and signal integration. Nat Immunol 7: 1266-1273. doi:10.1038/ni1411. PubMed: 17110943.
44. Flotho C, Claus R, Batz C, Schneider M, Sandrock I, et al. (2009) The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 23: 1019-1028. doi:10.1038/leu.2008.397. PubMed: 19194470.
45. Klco JM, Spencer DH, Lamprecht TL, Sarkaria SM, Wylie T, et al. (2013) Genomic impact of transient low-dose decitabine treatment on primary AML cells. Blood, 121: 1633-43. PubMed: 23297133.
46. Pandiyan K, You JS, Yang X, Dai C, Zhou XJ, et al. (2013) Functional DNA demethylation is accompanied by chromatin accessibility. Nucleic Acids Res, 41: 3973-85. PubMed: 23408854.
47. Si J, Boumber YA, Shu J, Qin T, Ahmed S, et al. (2010) Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation. Cancer Res 70: 6968-6977. doi:10.1158/0008-5472.CAN-09-4474. PubMed: 20713525.
48. Yang YT, Balch C, Kulp SK, Mand MR, Nephew KP, et al. (2009) A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer. Neoplasia 11: 552-563.following 563. PubMed: 19484144.
49. Chen MY, Liao WS, Lu Z, Bornmann WG, Hennessey V, et al. (2011) Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer 117: 4424-4438.
50. Stathis A, Hotte SJ, Chen EX, Hirte HW, Oza AM, et al. (2011) Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. Clin Cancer Res 17: 1582-1590. doi:10.1158/1078-0432.CCR-10-1893. PubMed: 21278245.